6 results about "Clindamycin" patented technology

This invention discloses the application of L-lysine in improving the sensitivity of Vibrio alginolyticus to clindamycin. This invention discovers that the combined use of L-lysine and clindamycin can significantly increase reactive oxygen species within Vibrio alginolyticus, thereby increasing the amount of clindamycin entering the bacteria and ultimately leading to bacterial death. Therefore, L-lysine can improve bacterial sensitivity to clindamycin, thus overcoming the problem of bacterial resistance. The small molecule metabolite provided by this invention, when used in combination with clindamycin, can significantly enhance the bactericidal effect of clindamycin, exhibiting better efficacy, higher safety, and greater operability compared to existing methods that use clindamycin alone as an antibacterial drug.

The invention belongs to the technical field of biology, and particularly relates to a bifidobacterium longum subsp. Longum FMBL B241768LS, a microbial inoculum and application of the microbial inoculum in hypoglycemic products, the bifidobacterium longum subsp. Longum FMBL B241768LS is preserved in China Center for Type Culture Collection on October 14, 2024, and the preservation number is CCTCC NO: M 20242173; the inhibitory activity of the compound on dipeptidyl peptidase IV is as high as 79.17%; the compound has a relatively good inhibition effect on the activity of alpha-glucosidase and alpha-amylase; the compound shows drug resistance to ciprofloxacin, ampicillin, penicillin G, clindamycin, kanamycin and polymyxin B; a good inhibition effect is achieved on pathogenic bacteria; the strain can be used for preparing medicines, fermented foods, health-care products and food additives for reducing blood sugar and inhibiting pathogenic bacteria, and has a wide application prospect.

The invention provides a pH response type porous modified Japanese banana core fiber multifunctional composite medical dressing and a preparation method thereof.The dressing takes Japanese banana core fibers with low crystallinity and high hydroxyl exposure degree as a base material, a porous network is formed through carboxymethylation modification, chitosan, baicalin and clindamycin are loaded, and the pH response type porous modified Japanese banana core fiber multifunctional composite medical dressing is obtained. The preparation method comprises the following steps: pretreating musa basjoo core fibers with an H2O2 solution containing disodium ethylene diamine tetraacetate to obtain short fibers, proportionally mixing the short fibers, chitosan and baicalin, adding the obtained mixture into a dissolution system, carrying out electrospinning to obtain a nanofiber membrane, carrying out freeze drying to construct a porous structure, and carrying out carboxymethylation modification and pH-responsive drug loading to obtain the antibacterial hydrogel. And finally, compounding collagen, rolling and sterilizing. The pH response type porous modified banana core fiber multifunctional composite medical dressing has the functions of pH sensitive drug release, efficient antibiosis, rapid hemostasis, wound repair promotion and the like, and high-valued utilization of waste banana core fibers is achieved.

Described herein is a method of predicting whether a bacterial vaginosis (BV) patient will respond to metronidazole treatment. The method comprises detecting a presence or absence of at least one of the Gardnerella vaginalis (Gv) genes selected from the group consisting of aruH, Ami, Cluster 1311, comEA, crcB, group_2326, group_2343, group_2558, group_2577, ssb, truB, yfeA, ykoD, and YneA, or an mRNA product, a protein product, or a metabolite thereof, in a sample from the patient. Also described herein is a method of treating, ameliorating, and / or preventing BV in a subject, which comprises administering to the subject an effective amount of metronidazole or an effective amount of clindamycin based on a prediction of whether the subject responds well to metronidazole treatment.

Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w / w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.

The invention relates to the technical field of drug carriers, in particular to a drug carrier for suppurative arthritis and a preparation method of the drug carrier. The drug carrier comprises liquid metal nanoparticles, a mesoporous material shell layer coating the liquid metal nanoparticles and a hyaluronic acid modification layer coating the mesoporous material shell layer, wherein liquid metal is gallium (Ga), gallium-indium alloy (GaIn), or ternary or multicomponent alloy containing gallium, indium and tin; the mesoporous material is at least one of mesoporous silica, mesoporous titanium dioxide and mesoporous carbon. The drug carrier can be used for loading different types of therapeutic agents (drugs) such as antibiotics (such as clindamycin), anti-inflammatory drugs and anti-tumor drugs, and the therapeutic agents can enter mesopores of the mesoporous material shell layer.